Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Hepatitis

  Free Subscription


Articles published in Clin Infect Dis

Retrieve available abstracts of 162 articles:
HTML format



Single Articles


    May 2020
  1. VALERIO H, Alavi M, Silk D, Treloar C, et al
    Progress towards elimination of hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage Study.
    Clin Infect Dis. 2020 May 18. pii: 5838577. doi: 10.1093.
    PubMed     Abstract available


  2. SETH A, Sherman KE
    Editorial: HCV Cure is the Start of the End For Those With Advanced Fibrosis/Cirrhosis.
    Clin Infect Dis. 2020 May 9. pii: 5835187. doi: 10.1093.
    PubMed    


  3. DIEZ C, Berenguer J, Ibanez-Samaniego L, Llop E, et al
    Persistence of clinically significant portal hypertension after eradication of HCV in patients with advanced cirrhosis.
    Clin Infect Dis. 2020 May 9. pii: 5835009. doi: 10.1093.
    PubMed     Abstract available


    April 2020
  4. CHAILLON A, Wynn A, Kushner T, Reau N, et al
    Cost-Effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States.
    Clin Infect Dis. 2020 Apr 13. pii: 5819607. doi: 10.1093.
    PubMed     Abstract available


  5. WONG CY, Zhu W, Aurigemma GP, Furukawa N, et al
    Infective endocarditis among persons aged 18-64 years with HIV, hepatitis C infection, or opioid use disorder - United States, 2007-2017.
    Clin Infect Dis. 2020 Apr 9. pii: 5818223. doi: 10.1093.
    PubMed     Abstract available


  6. ZHAO J, Liao X, Wang H, Wei L, et al
    Early virus clearance and delayed antibody response in a case of COVID-19 with a history of co-infection with HIV-1 and HCV.
    Clin Infect Dis. 2020 Apr 9. pii: 5818121. doi: 10.1093.
    PubMed     Abstract available


  7. DORE GJ, Cowie B
    Global Hepatitis B Virus Elimination by 2030: China Is Pivotal and Instructive.
    Clin Infect Dis. 2020 Apr 7. pii: 5817060. doi: 10.1093.
    PubMed    


  8. NAYAGAM S, Chan P, Zhao K, Sicuri E, et al
    Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning.
    Clin Infect Dis. 2020 Apr 7. pii: 5817057. doi: 10.1093.
    PubMed     Abstract available


    March 2020
  9. GARVEY LJ, Cooke GS, Smith C, Stingone C, et al
    Decline in Hepatitis C Virus (HCV) Incidence in Men Who Have Sex With Men Living With Human Immunodeficiency Virus: Progress to HCV Microelimination in the United Kingdom?
    Clin Infect Dis. 2020 Mar 25. pii: 5811003. doi: 10.1093.
    PubMed     Abstract available


  10. YIN S, Barker L, Ly KN, Kilmer G, et al
    Susceptibility to Hepatitis A Virus Infection in the United States, 2007-2016.
    Clin Infect Dis. 2020 Mar 20. pii: 5810334. doi: 10.1093.
    PubMed     Abstract available


  11. BAROCAS JA
    It's not them, it's us: Hepatitis C reinfection following successful treatment among people who inject drugs.
    Clin Infect Dis. 2020 Mar 12. pii: 5804221. doi: 10.1093.
    PubMed    


  12. CUNNINGHAM EB, Hajarizadeh B, Amin J, Hellard M, et al
    Reinfection following successful direct-acting antiviral therapy for hepatitis C infection among people who inject drugs.
    Clin Infect Dis. 2020 Mar 12. pii: 5804220. doi: 10.1093.
    PubMed     Abstract available


  13. BACH P, Ti L
    Hepatitis C and Stimulant use Disorder: Challenges and Opportunities.
    Clin Infect Dis. 2020 Mar 12. pii: 5803334. doi: 10.1093.
    PubMed    


    February 2020
  14. TERRAULT N
    Transplanting Kidneys from Donors with Chronic Hepatitis B: Bringing Transmission Risk Closer to Zero.
    Clin Infect Dis. 2020 Feb 25. pii: 5755200. doi: 10.1093.
    PubMed    


  15. ZELENEV A, Li J, Shea P, Hecht R, et al
    Modeling Combination HCV Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the USA.
    Clin Infect Dis. 2020 Feb 15. pii: 5736406. doi: 10.1093.
    PubMed     Abstract available


  16. MARCELLIN F, Miailhes P, Santos M, Mercie P, et al
    Cannabis use and plasma HIV RNA levels in HIV-HCV co-infected patients receiving antiretroviral therapy: data from the ANRS CO13 HEPAVIH cohort.
    Clin Infect Dis. 2020 Feb 14. pii: 5735646. doi: 10.1093.
    PubMed    


  17. POPPING S, Verwijs R, Cuypers L, Claassen M, et al
    Transmission of NS5A resistance associated substitutions among men-who-have-sex-with-men recently infected with hepatitis C virus genotype 1a.
    Clin Infect Dis. 2020 Feb 14. pii: 5735665. doi: 10.1093.
    PubMed     Abstract available


  18. LOK AS
    Is Sustained Virologic Response to Direct-Acting Antivirals a Valid Surrogate Endpoint for Clinical Outcomes of Hepatitis C?
    Clin Infect Dis. 2020 Feb 13. pii: 5734995. doi: 10.1093.
    PubMed    


  19. KRASSENBURG LAP, Zanjir WR, Georgie F, Stotland E, et al
    Evaluation of sustained virological response as a relevant surrogate endpoint for long-term outcomes of hepatitis C virus infection.
    Clin Infect Dis. 2020 Feb 13. pii: 5734994. doi: 10.1093.
    PubMed     Abstract available


  20. SPRINGER SA, Del Rio C
    Co-located opioid use disorder and HCV treatment is not only right but it is also the smart thing to do as it improves outcomes!
    Clin Infect Dis. 2020 Feb 3. pii: 5721551. doi: 10.1093.
    PubMed    


  21. ROSENTHAL ES, Silk R, Mathur P, Gross C, et al
    Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs.
    Clin Infect Dis. 2020 Feb 3. pii: 5721142. doi: 10.1093.
    PubMed     Abstract available


    January 2020
  22. FARAG MS, van Campenhout MJH, Pfefferkorn M, Fischer J, et al
    Hepatitis B virus RNA as Early Predictor for Response to PEGylated Interferon Alfa in HBeAg Negative Chronic Hepatitis B.
    Clin Infect Dis. 2020 Jan 8. pii: 5698122. doi: 10.1093.
    PubMed     Abstract available


    December 2019
  23. BUTT AA, Yan P, Aslam S, Abou-Samra AB, et al
    Liver Fibrosis Progression and Mortality in Hepatitis B- and C-Coinfected Persons Treated With Directly Acting Antiviral Agents: Results From ERCHIVES.
    Clin Infect Dis. 2019 Dec 16. pii: 5678676. doi: 10.1093/cid/ciz1097.
    PubMed     Abstract available


  24. SINGH KP, Lewin SR
    Hepatitis B infection in people living with HIV - a global challenge needing more research.
    Clin Infect Dis. 2019 Dec 9. pii: 5669954. doi: 10.1093/cid/ciz1175.
    PubMed    


  25. LEUMI S, Bigna JJ, Amougou MA, Ngouo A, et al
    Global burden of hepatitis B infection in people living with HIV: a systematic review and meta-analysis.
    Clin Infect Dis. 2019 Dec 9. pii: 5669955. doi: 10.1093/cid/ciz1170.
    PubMed     Abstract available


  26. KAMAR N, Abravanel F, Behrendt P, Hofmann J, et al
    Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study.
    Clin Infect Dis. 2019 Dec 3. pii: 5650877. doi: 10.1093.
    PubMed     Abstract available


  27. CRUM-CIANFLONE NF
    Therapy for Chronic Hepatitis E Virus Infection-Current Recommendations and Future Aspirations.
    Clin Infect Dis. 2019 Dec 3. pii: 5650876. doi: 10.1093.
    PubMed    


    November 2019
  28. OGAWA E, Toyoda H, Iio E, Jun DW, et al
    HCV Cure Rates are Reduced in Patients with Active but not Inactive Hepatocellular Carcinoma- A Practice Implication.
    Clin Infect Dis. 2019 Nov 28. pii: 5645107. doi: 10.1093/cid/ciz1160.
    PubMed     Abstract available


  29. CORMA-GOMEZ A, Macias J, Tellez F, Freyre-Carrillo C, et al
    Liver stiffness at the time of sustained virological response predicts the clinical outcome in HIV/HCV-coinfected patients with advanced fibrosis treated with direct-acting antivirals.
    Clin Infect Dis. 2019 Nov 22. pii: 5637523. doi: 10.1093/cid/ciz1140.
    PubMed     Abstract available


  30. CUNNINGHAM EB, Hajarizadeh B, Amin J, Litwin AH, et al
    Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy.
    Clin Infect Dis. 2019 Nov 2. pii: 5611150. doi: 10.1093/cid/ciz1089.
    PubMed     Abstract available


    October 2019
  31. SCHULTE B, Schmidt CS, Strada L, Rosenkranz M, et al
    Hepatitis C Virus Prevalence and Incidence in a Large Nationwide Sample of Patients in Opioid Substitution Treatment in Germany: A Prospective Cohort Study.
    Clin Infect Dis. 2019 Oct 21. pii: 5601291. doi: 10.1093.
    PubMed     Abstract available


  32. LIN KY, Lee YL, Huang SH, Chen GJ, et al
    Public health intervention strategies to contain hepatitis A outbreak.
    Clin Infect Dis. 2019 Oct 14. pii: 5586740. doi: 10.1093/cid/ciz1002.
    PubMed    


  33. MERAT S
    Erratum to: SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial.
    Clin Infect Dis. 2019 Oct 12. pii: 5586681. doi: 10.1093.
    PubMed    


  34. LY KN, Minino AM, Liu SJ, Roberts H, et al
    Deaths Associated with Hepatitis C Virus Infection among Residents in 50 States and the District of Columbia, 2016-2017.
    Clin Infect Dis. 2019 Oct 5. pii: 5581721. doi: 10.1093.
    PubMed     Abstract available


  35. MARTINELLO M, Yee J, Bartlett SR, Read P, et al
    Moving towards hepatitis C micro-elimination among people living with HIV in Australia: the CEASE study.
    Clin Infect Dis. 2019 Oct 4. pii: 5581531. doi: 10.1093.
    PubMed     Abstract available


    September 2019
  36. TSERTSVADZE T, Gamkrelidze A, Chkhartishvili N, Abutidze A, et al
    Three years of progress towards achieving hepatitis C elimination in the country of Georgia, April 2015 - March 2018.
    Clin Infect Dis. 2019 Sep 29. pii: 5575959. doi: 10.1093.
    PubMed     Abstract available


  37. FALADE-NWULIA O
    HCV Elimination requires more than Good Drugs.
    Clin Infect Dis. 2019 Sep 29. pii: 5575956. doi: 10.1093.
    PubMed    


  38. CHROMY D, Schmidt R, Mandorfer M, Lang GF, et al
    HCV-RNA is commonly detectable in rectal and nasal fluids of patients with high viremia.
    Clin Infect Dis. 2019 Sep 28. pii: 5575905. doi: 10.1093.
    PubMed     Abstract available


  39. INGILIZ P, Wehmeyer MH, Boesecke C, Schulze Zur Wiesch J, et al
    Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany: Current incidence rates compared with rates during the interferon era.
    Clin Infect Dis. 2019 Sep 28. pii: 5575902. doi: 10.1093.
    PubMed     Abstract available


  40. GRAF C, Mucke MM, Dultz G, Peiffer KH, et al
    Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.
    Clin Infect Dis. 2019 Sep 12. pii: 5568364. doi: 10.1093.
    PubMed     Abstract available


  41. NORTON BL, Litwin AH
    A Call to Action: HCV Treatment of People Who Inject Drugs in the United States.
    Clin Infect Dis. 2019 Sep 12. pii: 5568312. doi: 10.1093.
    PubMed    


    August 2019
  42. SAEED S, Strumpf E, Moodie EEM, Wong L, et al
    Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake among People Living with HIV.
    Clin Infect Dis. 2019 Aug 28. pii: 5555890. doi: 10.1093.
    PubMed     Abstract available


  43. MCMAHON BJ, Townshend-Bulson L, Homan C, Gounder P, et al
    Cascade of Care for Alaska Native People with Chronic Hepatitis C Virus Infection: Statewide Program with High Linkage to Care.
    Clin Infect Dis. 2019 Aug 28. pii: 5555891. doi: 10.1093.
    PubMed     Abstract available


  44. KOIBUCHI T, Koga M, Kikuchi T, Horikomi T, et al
    Prevalence of hepatitis A immunity and decision-tree analysis among HIV-infected men who have sex with men, in Tokyo.
    Clin Infect Dis. 2019 Aug 26. pii: 5554745. doi: 10.1093.
    PubMed     Abstract available


  45. KUSHNER T, Chen Z, Tressler S, Kaufman H, et al
    Trends in Hepatitis B Infection and Immunity among Women of Childbearing Age in the United States.
    Clin Infect Dis. 2019 Aug 26. pii: 5554743. doi: 10.1093.
    PubMed     Abstract available


  46. PEAK CM, Stous SS, Healy JM, Hofmeister MG, et al
    Homelessness and Hepatitis A - San Diego County, 2016-2018.
    Clin Infect Dis. 2019 Aug 15. pii: 5550168. doi: 10.1093.
    PubMed     Abstract available


  47. STEVENS ER, Nucifora KA, Hagan H, Jordan AE, et al
    Cost-effectiveness of direct anti-viral agents for hepatitis C virus infection and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population.
    Clin Infect Dis. 2019 Aug 11. pii: 5546014. doi: 10.1093.
    PubMed     Abstract available


  48. SUN L, Fan J, Gao H, Shan L, et al
    Background End-stage Liver Diseases but not Pure HBV Infection Exacerbate Clinical Outcomes in Patients with Acute Hepatitis E.
    Clin Infect Dis. 2019 Aug 1. pii: 5542442. doi: 10.1093.
    PubMed    


    July 2019
  49. SAFREED-HARMON K, Blach S, Aleman S, Boe Kielland K, et al
    The Consensus Hepatitis C Cascade of Care: standardized reporting to monitor progress toward elimination.
    Clin Infect Dis. 2019 Jul 28. pii: 5540024. doi: 10.1093.
    PubMed     Abstract available


  50. SHING JZ, Ly KN, Xing J, Teshale EH, et al
    Prevalence of Hepatitis B Virus Infection among US Adults Aged 20-59 Years with a History of Injection Drug Use: National Health and Nutrition Examination Survey, 2001-2016.
    Clin Infect Dis. 2019 Jul 27. pii: 5539881. doi: 10.1093.
    PubMed     Abstract available


  51. AKIYAMA MJ, Lipsey D, Heo M, Agyemang L, et al
    Low Hepatitis C Reinfection Following Direct-Acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.
    Clin Infect Dis. 2019 Jul 26. pii: 5538954. doi: 10.1093.
    PubMed     Abstract available


  52. SPRINGER SA
    HCV reinfection is low among persons who use drugs maintained on medication treatment for Opioid Use Disorder.
    Clin Infect Dis. 2019 Jul 26. pii: 5538956. doi: 10.1093.
    PubMed    


  53. ARTENIE AA, Cunningham EB, Dore GJ, Conway B, et al
    Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: An international s
    Clin Infect Dis. 2019 Jul 11. pii: 5531892. doi: 10.1093.
    PubMed     Abstract available


  54. MERAT S
    SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial.
    Clin Infect Dis. 2019 Jul 10. pii: 5531032. doi: 10.1093.
    PubMed     Abstract available


  55. COOPER C
    Eliminating Hepatitis C (and the Unknowns) in the HIV Co-Infected.
    Clin Infect Dis. 2019 Jul 2. pii: 5527234. doi: 10.1093.
    PubMed    


  56. MOCROFT A, Lundgren J, Gerstoft J, Rasmussen LD, et al
    Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment.
    Clin Infect Dis. 2019 Jul 2. pii: 5527213. doi: 10.1093.
    PubMed     Abstract available


    June 2019
  57. WADE AJ, Doyle JS, Gane E, Stedman C, et al
    Outcomes of treatment for hepatitis C in primary care compared to hospital-based care: a randomised controlled trial in people who inject drugs.
    Clin Infect Dis. 2019 Jun 22. pii: 5522438. doi: 10.1093.
    PubMed     Abstract available


  58. KING H, Xing J, Dean HD, Holtzman D, et al
    Trends in prevalence of protective levels of hepatitis B surface antibody among adults aged 18-49 years with risk factors for hepatitis B virus infection-United States, 2003-2014.
    Clin Infect Dis. 2019 Jun 20. pii: 5522094. doi: 10.1093.
    PubMed     Abstract available


  59. LIN KY, Sun HY, Chen YH, Lo YC, et al
    Effect of a hepatitis A vaccination campaign during a hepatitis A outbreak in Taiwan, 2015-2017: a modeling study.
    Clin Infect Dis. 2019 Jun 3. pii: 5510337. doi: 10.1093.
    PubMed     Abstract available


    May 2019
  60. MACDONALD BR, Chu TC, Stewart RA, Ojha RP, et al
    Setting-Based Prioritization for Birth Cohort Hepatitis C Virus Testing in the United States.
    Clin Infect Dis. 2019 May 24. pii: 5498354. doi: 10.1093.
    PubMed    


  61. SHIMAKAWA Y, Ndow G, Njie R, Njai HF, et al
    Hepatitis B core-related antigen (HBcrAg): an alternative to HBV DNA to assess treatment eligibility in Africa.
    Clin Infect Dis. 2019 May 17. pii: 5491470. doi: 10.1093.
    PubMed     Abstract available


  62. GUTKIND S, Schackman BR, Morgan JR, Leff JA, et al
    Cost-effectiveness of HCV Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs.
    Clin Infect Dis. 2019 May 16. pii: 5490664. doi: 10.1093.
    PubMed     Abstract available


  63. ASSOUMOU SA, Tasillo A, Vellozzi C, Yazdi GE, et al
    Cost-effectiveness and budgetary impact of HCV testing, treatment and linkage to care in U.S. prisons.
    Clin Infect Dis. 2019 May 16. pii: 5490662. doi: 10.1093.
    PubMed     Abstract available


  64. HARRINGTON PR, Komatsu TE, Sun H, Naeger LK, et al
    HCV RNA Levels Following Virologic Failure with Direct-Acting Antivirals: Implications for Lower Sensitivity Diagnostic Assays.
    Clin Infect Dis. 2019 May 10. pii: 5487938. doi: 10.1093.
    PubMed     Abstract available


  65. TOYODA H, Tada T, Yasuda S, Mizuno K, et al
    Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Who Achieved Sustained Virologic Response.
    Clin Infect Dis. 2019 May 6. pii: 5485915. doi: 10.1093.
    PubMed     Abstract available


    April 2019
  66. BUTT AA, Yan P, Aslam S, Shaikh OS, et al
    Hepatitis C Virus Treatment with Directly Acting Agents Reduces the Risk of Incident Diabetes - Results from ERCHIVES.
    Clin Infect Dis. 2019 Apr 12. pii: 5448895. doi: 10.1093.
    PubMed     Abstract available


  67. YOUNOSSI ZM, Stepanova M, Jacobson I, Muir AJ, et al
    Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening of Patient-Reported Outcomes.
    Clin Infect Dis. 2019 Apr 5. pii: 5428146. doi: 10.1093.
    PubMed     Abstract available


  68. BERTISCH B, Brezzi M, Negro F, Mullhaupt B, et al
    Very low hepatitis C viral loads in treatment-naive persons: do they compromise hepatitis C virus antigen testing?
    Clin Infect Dis. 2019 Apr 3. pii: 5426964. doi: 10.1093.
    PubMed     Abstract available


  69. MATHUR P, Kottilil S
    Hepatitis C core antigen testing: Still an effective diagnostic method for global elimination of hepatitis C.
    Clin Infect Dis. 2019 Apr 3. pii: 5426965. doi: 10.1093.
    PubMed    


  70. SORIANO V, Gomez-Gallego F, Corral O
    Hepatitis delta estimates in the United States revisited.
    Clin Infect Dis. 2019 Apr 3. pii: 5426967. doi: 10.1093.
    PubMed    


    March 2019
  71. SALVADORI N, Fan B, Teeyasoontranon W, Ngo-Giang-Huong N, et al
    Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus.
    Clin Infect Dis. 2019 Mar 29. pii: 5422240. doi: 10.1093.
    PubMed     Abstract available


  72. GANE E, Poordad F, Zadeikis N, Valdes J, et al
    Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.
    Clin Infect Dis. 2019 Mar 28. pii: 5421746. doi: 10.1093.
    PubMed     Abstract available


  73. KISER JJ
    Safety of Hepatitis C Viral Protease Inhibitors in Compensated Cirrhotics: Lingering Concerns Put to Rest?
    Clin Infect Dis. 2019 Mar 28. pii: 5421743. doi: 10.1093.
    PubMed    


  74. NAGGIE S, Fierer DS, Hughes MD, Kim AY, et al
    Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
    Clin Infect Dis. 2019 Mar 28. pii: 5421820. doi: 10.1093.
    PubMed     Abstract available


  75. LUI GCY, Wong NS, Wong RYK, Tse YK, et al
    Antiviral therapy for hepatitis B prevents liver injury in patients with tuberculosis and hepatitis B co-infection.
    Clin Infect Dis. 2019 Mar 22. pii: 5421304. doi: 10.1093.
    PubMed     Abstract available


    February 2019
  76. BOETTIGER DC, Salazar-Vizcaya L, Dore GJ, Gray RT, et al
    Can Australia reach the World Health Organization Hepatitis C elimination goal by 2025 among HIV-positive gay and bisexual men?
    Clin Infect Dis. 2019 Feb 28. pii: 5366676. doi: 10.1093.
    PubMed     Abstract available


  77. GEDDES L, Iversen J, Wand H, Esmaeili A, et al
    Sex discrepancies in the protective effect of opioid agonist therapy on incident hepatitis C infection.
    Clin Infect Dis. 2019 Feb 28. pii: 5366653. doi: 10.1093.
    PubMed     Abstract available


  78. CHEN SH, Lai HC, Chiang IP, Su WP, et al
    Performance of Acoustic Radiation Force Impulse Elastography for Staging Liver Fibrosis in Patients with Chronic Hepatitis C after Viral Eradication.
    Clin Infect Dis. 2019 Feb 28. pii: 5366592. doi: 10.1093.
    PubMed     Abstract available


  79. RAMIERE C, Charre C, Miailhes P, Bailly F, et al
    Patterns of HCV transmission in HIV-infected and HIV-negative men having sex with men.
    Clin Infect Dis. 2019 Feb 27. pii: 5365873. doi: 10.1093.
    PubMed     Abstract available


  80. BROUWER WP, Chan HL, Lampertico P, Hou J, et al
    Genome Wide Association Study Identifies Genetic Variants Associated With Early And Sustained Response To (Peg)Interferon In Chronic Hepatitis B Patients: The GIANT-B Study.
    Clin Infect Dis. 2019 Feb 2. pii: 5305981. doi: 10.1093.
    PubMed     Abstract available


  81. CHAUDHURY CS, Mee T, Chairez C, McLaughlin M, et al
    Testosterone in Men With Chronic Hepatitis C Infection and After Hepatitis C Viral Clearance.
    Clin Infect Dis. 2019 Feb 2. pii: 5305922. doi: 10.1093.
    PubMed     Abstract available


  82. BROWN TT
    Hypogonadism in Men With Hepatitis C: What Is a Clinician to Do?
    Clin Infect Dis. 2019 Feb 2. pii: 5305923. doi: 10.1093.
    PubMed    


    January 2019
  83. CHAILLON A, Rand EB, Reau N, Martin NK, et al
    Cost-Effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in The United States.
    Clin Infect Dis. 2019 Jan 28. pii: 5303781. doi: 10.1093.
    PubMed     Abstract available


  84. MCAULEY JB, Close R
    Better Guidance on Treating HCV in Pregnancy: The Time is Now.
    Clin Infect Dis. 2019 Jan 7. pii: 5275237. doi: 10.1093.
    PubMed    


  85. BRESKIN A, Westreich D, Hurt CB, Cole SR, et al
    The effects of hepatitis C treatment eligibility criteria on all-cause mortality among people with HIV.
    Clin Infect Dis. 2019 Jan 7. pii: 5274661. doi: 10.1093.
    PubMed     Abstract available


  86. PATEL EU, Thio CL, Boon D, Thomas DL, et al
    Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011-2016.
    Clin Infect Dis. 2019 Jan 3. pii: 5272449. doi: 10.1093.
    PubMed     Abstract available


    December 2018
  87. LOOMBA R, Decaris M, Li KW, Shankaran M, et al
    Discovery of half-life of circulating HBsAg in patients with chronic hepatitis B infection using heavy water labeling.
    Clin Infect Dis. 2018 Dec 24. pii: 5259172. doi: 10.1093/cid/ciy1100.
    PubMed     Abstract available


    October 2018
  88. TALAL AH, Andrews P, Mcleod A, Chen Y, et al
    Integrated, Co-located, Telemedicine-based Treatment Approaches for Hepatitis C Virus (HCV) Management in Opioid Use Disorder Patients on Methadone.
    Clin Infect Dis. 2018 Oct 17. pii: 5133592. doi: 10.1093.
    PubMed     Abstract available


  89. BRESKIN A, Westreich D, Cole SR, Hudgens MG, et al
    The Effects of Hepatitis C Infection and Treatment on All-cause Mortality Among People Living With Human Immunodeficiency Virus.
    Clin Infect Dis. 2018 Oct 12. pii: 5128783. doi: 10.1093.
    PubMed     Abstract available


    September 2018
  90. TIO SY, Nickless D, McCracken J, Nedumannil R, et al
    A Man With Tonsillitis and Hepatitis.
    Clin Infect Dis. 2018;67:1303-1305.
    PubMed    


  91. LAI JC, Wong GL, Yip TC, Tse YK, et al
    Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From 2000 to 2016.
    Clin Infect Dis. 2018;67:1278-1284.
    PubMed     Abstract available


  92. PATEL EU, Mehta SH, Boon D, Quinn TC, et al
    Limited Coverage of Hepatitis C Virus Testing in the United States, 2013-2017.
    Clin Infect Dis. 2018 Sep 15. pii: 5098442. doi: 10.1093.
    PubMed     Abstract available



  93. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
    Clin Infect Dis. 2018 Sep 12. pii: 5095352. doi: 10.1093.
    PubMed     Abstract available


  94. JHAVERI R, Broder T, Bhattacharya D, Peters MG, et al
    Universal Screening of Pregnant Women for Hepatitis C: The Time Is Now.
    Clin Infect Dis. 2018 Sep 12. pii: 5095353. doi: 10.1093.
    PubMed     Abstract available


    August 2018
  95. BUTT AA, Yan P, Lo Re V 3rd, Shaikh OS, et al
    Trends in Treatment Uptake and Provider Specialty for HCV Infection in the VA Healthcare System: Results from ERCHIVES.
    Clin Infect Dis. 2018 Aug 22. pii: 5077936. doi: 10.1093.
    PubMed     Abstract available


  96. SULKOWSKI MS
    The Proof Is in the Patient: Hepatitis C Virus Microelimination in the Swiss Human Immunodeficiency Virus Cohort Study.
    Clin Infect Dis. 2018 Aug 13. pii: 5071944. doi: 10.1093.
    PubMed    


  97. BRAUN DL, Hampel B, Martin E, Kouyos R, et al
    High Number of Potential Transmitters Revealed in a Population-based Systematic Hepatitis C Virus RNA Screening Among Human Immunodeficiency Virus-infected Men Who Have Sex With Men.
    Clin Infect Dis. 2018 Aug 13. pii: 5071946. doi: 10.1093.
    PubMed     Abstract available


  98. BRAUN DL, Hampel B, Kouyos R, Nguyen H, et al
    High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.
    Clin Infect Dis. 2018 Aug 13. pii: 5071945. doi: 10.1093.
    PubMed     Abstract available


    July 2018
  99. BIXLER D, Zhong Y, Ly KN, Moorman AC, et al
    Mortality among Patients with Chronic Hepatitis B (CHB) Infection: the Chronic Hepatitis Cohort Study (CHeCS).
    Clin Infect Dis. 2018 Jul 28. pii: 5061152. doi: 10.1093.
    PubMed     Abstract available


  100. SMITH D, Huynh C, Moore AJ, Frick A, et al
    Herd Immunity Likely Protected the Men who have Sex with Men in Recent Hepatitis A Outbreak in San Diego CA.
    Clin Infect Dis. 2018 Jul 25. pii: 5059685. doi: 10.1093.
    PubMed     Abstract available


    June 2018
  101. KILMER GA, Barker LK, Ly KN, Jiles RB, et al
    Hepatitis B vaccination and screening among foreign-born women of reproductive age in the United States: 2013-2015.
    Clin Infect Dis. 2018 Jun 1. pii: 5026244. doi: 10.1093.
    PubMed     Abstract available


    May 2018
  102. HOSRY J, Angelidakis G, Kaseb A, Jiang Y, et al
    Inhibition of Hepatitis C Virus Replication Induced by Chemotherapy: A Prospective Observational Study.
    Clin Infect Dis. 2018 May 15. pii: 4996053. doi: 10.1093.
    PubMed    


  103. ALROY-PREIS S, Daly ER, Adamski C, Dionne-Odom J, et al
    Large Outbreak of Hepatitis C Virus Associated With Drug Diversion by a Healthcare Technician.
    Clin Infect Dis. 2018 May 14. pii: 4995993. doi: 10.1093.
    PubMed     Abstract available


  104. MEISSNER EG
    The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression?
    Clin Infect Dis. 2018 May 1. pii: 4989914. doi: 10.1093.
    PubMed    


  105. INOUE T, Nakayama J, Moriya K, Kawaratani H, et al
    Gut Dysbiosis Associated With Hepatitis C Virus Infection.
    Clin Infect Dis. 2018 May 1. pii: 4989908. doi: 10.1093.
    PubMed     Abstract available


    April 2018
  106. HECTOR J, Vinikoor M, Chilengi R, Ehmer J, et al
    No Impact of Hepatitis B Virus Infection on Early Mortality among HIV-infected Patients in Southern Africa.
    Clin Infect Dis. 2018 Apr 18. pii: 4975531. doi: 10.1093.
    PubMed    


  107. LEE YL, Chen GJ, Chen NY, Liou BH, et al
    Less Severe but Prolonged Course of Acute Hepatitis A in HIV-positive Patients than HIV-negative Patients During an Outbreak: A Multicenter Observational Study.
    Clin Infect Dis. 2018 Apr 17. pii: 4972863. doi: 10.1093.
    PubMed     Abstract available


  108. MELLIEZ H, Mary-Krause M, Bocket L, Guiguet M, et al
    Risk of Progressive Multifocal Leukoencephalopathy in the Combination Antiretroviral Therapy Era in the French Hospital Database on Human Immunodeficiency Virus (ANRS-C4).
    Clin Infect Dis. 2018 Apr 4. pii: 4960877. doi: 10.1093.
    PubMed     Abstract available


    March 2018
  109. WALKER A, Boyce A, Geller G, Thio CL, et al
    Direct Acting Antivirals and Hepatitis C: The Ethics of Price and Rationing by Genotype.
    Clin Infect Dis. 2018 Mar 29. pii: 4956154. doi: 10.1093.
    PubMed    


  110. ROCKSTROH JK, Lacombe K, Viani RM, Orkin C, et al
    Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1: the EXPEDITION-2 Study.
    Clin Infect Dis. 2018 Mar 16. pii: 4939381. doi: 10.1093.
    PubMed     Abstract available


  111. BARTLETT SR, Fox P, Cabatingan H, Jaros A, et al
    Demonstration of near-elimination of hepatitis C virus among a prison population: the Lotus Glen Correctional Centre hepatitis C treatment project.
    Clin Infect Dis. 2018 Mar 12. pii: 4930770. doi: 10.1093.
    PubMed     Abstract available


  112. KLEINSTEIN SE, Shea PR, Stamm LM, Sulkowski M, et al
    Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.
    Clin Infect Dis. 2018 Mar 7. pii: 4705930. doi: 10.1093/cid/cix1051.
    PubMed     Abstract available


  113. MOGALIAN E, Stamm LM, Osinusi A, Brainard DM, et al
    Drug-Drug Interactions Studies between HCV Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted HIV Antiretroviral Regimens in Healthy Volunteers.
    Clin Infect Dis. 2018 Mar 7. pii: 4924529. doi: 10.1093.
    PubMed     Abstract available


    February 2018
  114. BAROCAS JA, Tasillo A, Eftekhari Yazdi G, Wang J, et al
    Population level outcomes and cost-effectiveness of expanding the recommendation for age-based hepatitis C testing in the United States.
    Clin Infect Dis. 2018 Feb 6. pii: 4840186. doi: 10.1093.
    PubMed     Abstract available


    January 2018
  115. TROPPY S, Soliva S, Onofrey S, DeMaria A Jr., et al
    Geographic Disparities in Access to Syringe Services Programs Among Young Persons with Hepatitis C Virus Infection in Massachusetts.
    Clin Infect Dis. 2018 Jan 31. pii: 4831117. doi: 10.1093.
    PubMed    


    December 2017
  116. HUA S, Vigano S, Tse S, Zhengyu O, et al
    Pegylated IFN-alpha-induced NK cell activation is associated with HIV-1 DNA decline in ART-treated HIV-1/HCV co-infected patients.
    Clin Infect Dis. 2017 Dec 20. pii: 4767848. doi: 10.1093/cid/cix1111.
    PubMed     Abstract available


  117. YOUNOSSI ZM, Stepanova M, Asselah T, Foster G, et al
    Hepatitis C in Patients with Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes.
    Clin Infect Dis. 2017 Dec 20. pii: 4766885. doi: 10.1093/cid/cix1106.
    PubMed     Abstract available


  118. RICKLES M, Rebeiro PF, Sizemore L, Juarez P, et al
    Tennessee's In-State Vulnerability Assessment for a 'Rapid Dissemination of HIV or HCV Infection' Event Utilizing Data about the Opioid Epidemic.
    Clin Infect Dis. 2017 Dec 7. pii: 4706246. doi: 10.1093/cid/cix1079.
    PubMed     Abstract available


  119. KAPADIA SN, Jeng PJ, Schackman BR, Bao Y, et al
    State Medicaid hepatitis C treatment eligibility criteria and use of direct acting antivirals.
    Clin Infect Dis. 2017 Dec 1. pii: 4682615. doi: 10.1093/cid/cix1062.
    PubMed     Abstract available


    November 2017
  120. BOEREKAMPS A, Newsum AM, Smit C, Arends JE, et al
    High treatment uptake in HIV/HCV-coinfected patients after unrestricted access to direct-acting antivirals in the Netherlands.
    Clin Infect Dis. 2017 Nov 23. pii: 4654728. doi: 10.1093/cid/cix1004.
    PubMed     Abstract available


  121. ROCKSTROH JK
    Is HCV elimination in well-defined patient groups possible?
    Clin Infect Dis. 2017 Nov 23. pii: 4654730. doi: 10.1093/cid/cix1010.
    PubMed    


  122. BOEREKAMPS A, Van den Berk GE, Fanny LN, Leyten EM, et al
    Declining HCV incidence in Dutch HIV positive men who have sex with men after unrestricted access to HCV therapy.
    Clin Infect Dis. 2017 Nov 23. pii: 4654729. doi: 10.1093/cid/cix1007.
    PubMed     Abstract available


  123. BEDIMO RJ, Adams-Huet B, Poindexter J, Brown G, et al
    The Differential Effects of HIV and HCV on Bone Micro-Architecture and Fracture risk.
    Clin Infect Dis. 2017 Nov 14. doi: 10.1093/cid/cix1011.
    PubMed     Abstract available


    October 2017
  124. DE LEDINGHEN V, Laforest C, Hezode C, Pol S, et al
    Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed a NS5A or NS3-containing regimen. ANRS HC34 REVENGE.
    Clin Infect Dis. 2017 Oct 25. doi: 10.1093.
    PubMed     Abstract available


  125. YAYA I, Costa M, Marcellin F, Miailhes P, et al
    Gender, alcohol use and fibrosis in HIV-HCV co-infected individuals.
    Clin Infect Dis. 2017 Oct 23. doi: 10.1093.
    PubMed    


  126. PARR JB, Lodge EK, Holzmayer V, Pepin J, et al
    An Efficient, Large-Scale Survey of Hepatitis C Viremia in the Democratic Republic of the Congo Using Dried Blood Spots.
    Clin Infect Dis. 2017 Oct 18. doi: 10.1093.
    PubMed     Abstract available


    September 2017
  127. BUTT AA, Yan P, Simon TG, Abou-Samra AB, et al
    Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES.
    Clin Infect Dis. 2017;65:1006-1011.
    PubMed     Abstract available


  128. HASHEM M, Jhaveri R, Saleh DA, Sharaf SA, et al
    Spontaneous Viral Load Decline and Subsequent Clearance of Chronic Hepatitis C Virus in Postpartum Women Correlates With Favorable Interleukin-28B Gene Allele.
    Clin Infect Dis. 2017;65:999-1005.
    PubMed     Abstract available


  129. PIROTH L, Launay O, Miailhes P, Carrat F, et al
    Isolated anti-HBc serological profile: has the time come to vaccinate?
    Clin Infect Dis. 2017 Sep 15. doi: 10.1093.
    PubMed    


  130. ASSOUMOU SA, Tasillo A, Leff JA, Schackman BR, et al
    The cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings.
    Clin Infect Dis. 2017 Sep 9. doi: 10.1093.
    PubMed     Abstract available


  131. CHHATWAL J
    Hepatitis C screening: From modeling to public health policy.
    Clin Infect Dis. 2017 Sep 9. doi: 10.1093.
    PubMed    


  132. LIU CH, Chen YS, Wang SS, Liu CJ, et al
    Sofosbuvir-based interferon-free direct acting antiviral regimens for heart transplant recipients with chronic hepatitis C virus infection.
    Clin Infect Dis. 2017 Sep 4. doi: 10.1093.
    PubMed     Abstract available


  133. WEINBERG EM, Reddy KR
    Let's Make a Deal: Shortening the solid organ transplant waiting time in exchange for transmitting and treating Hepatitis C infection in the era of safe and effective DAAs.
    Clin Infect Dis. 2017 Sep 4. doi: 10.1093.
    PubMed    


    August 2017
  134. ESMAEILI A, Mirzazadeh A, Morris MD, Hajarizadeh B, et al
    The effect of female sex on hepatitis C incidence among people who inject drugs: results from the international multi-cohort InC3 Collaborative.
    Clin Infect Dis. 2017 Aug 24. doi: 10.1093.
    PubMed     Abstract available


  135. ABRAHAM GM, Spooner LM
    Citius Altius Fortius: The New Paradigm In The Treatment Of Chronic Hepatitis C Disease.
    Clin Infect Dis. 2017 Aug 21. doi: 10.1093.
    PubMed     Abstract available


  136. KOUAME GM, Boyd A, Moh R, Badje A, et al
    Higher mortality despite early ART in HIV and hepatitis B virus coinfected patients with high HBV replication.
    Clin Infect Dis. 2017 Aug 19. doi: 10.1093.
    PubMed     Abstract available


  137. WANG H, Wan Z, Xu R, Guan Y, et al
    A Novel Human Pegivirus HPgV-2 (HHpgV-1) is Tightly Associated with HCV Infection and HCV/HIV-1 Co-Infection.
    Clin Infect Dis. 2017 Aug 19. doi: 10.1093.
    PubMed     Abstract available


  138. KELLY EM, Dodge JL, Bacchetti P, Sarkar M, et al
    Moderate Alcohol use is not Associated with Fibrosis Progression in HIV/HCV Co-Infected Women: A Prospective Cohort Study.
    Clin Infect Dis. 2017 Aug 16. doi: 10.1093.
    PubMed     Abstract available


  139. LO RE V 3RD
    Is Moderate Alcohol Consumption Safe for HIV/Hepatitis C Virus-Coinfected Women?
    Clin Infect Dis. 2017 Aug 16. doi: 10.1093.
    PubMed    


  140. BYRNE DD, Tate JP, Forde KA, Lim JK, et al
    Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status.
    Clin Infect Dis. 2017 Aug 16. doi: 10.1093.
    PubMed     Abstract available


    July 2017
  141. SARKAR M, Dodge JL, Greenblatt RM, Kuniholm MH, et al
    Reproductive Aging and Hepatic Fibrosis Progression in HIV/Hepatitis C Virus Co-Infected Women.
    Clin Infect Dis. 2017 Jul 26. doi: 10.1093.
    PubMed     Abstract available


  142. POWDERLY WG, Naggie S, Kim AY, Vargas HE, et al
    IDSA/AASLD response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C.
    Clin Infect Dis. 2017 Jul 17. doi: 10.1093.
    PubMed    


    June 2017
  143. CHI H, Wong D, Peng J, Cao J, et al
    Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation.
    Clin Infect Dis. 2017 Jun 1. doi: 10.1093.
    PubMed     Abstract available


    May 2017
  144. KIM AY
    The National Academy Report on the Elimination of Viral Hepatitis: An Infectious Disease Physician's Perspective.
    Clin Infect Dis. 2017 May 27. doi: 10.1093.
    PubMed    


  145. FELD JJ, Ramji A, Shafran SD, Willems B, et al
    Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.
    Clin Infect Dis. 2017 May 23. doi: 10.1093.
    PubMed     Abstract available


  146. ZUCMAN D, Farfour E, Mazaux L, Hillaire S, et al
    How to face the outbreak of viral hepatitis A in men-who-have-sex-with-men in France without vaccines?
    Clin Infect Dis. 2017 May 16. doi: 10.1093.
    PubMed    


  147. BOSCHI C, Colson P, Tissot-Dupont H, Bernit E, et al
    Hepatitis C virus relapse 78 weeks after completion of successful direct acting therapy.
    Clin Infect Dis. 2017 May 16. doi: 10.1093.
    PubMed    


  148. MOON J, Hyland RH, Zhang F, Brainard DM, et al
    Efficacy and safety of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C in persons with sickle cell disease.
    Clin Infect Dis. 2017 May 13. doi: 10.1093.
    PubMed     Abstract available


    April 2017
  149. ROSENBERG ES, Hall EW, Sullivan PS, Sanchez TH, et al
    Estimation of State-Level Prevalence of Hepatitis C Virus Infection, US States and District of Columbia, 2010.
    Clin Infect Dis. 2017 Apr 26. doi: 10.1093.
    PubMed     Abstract available


  150. OZARAS R, Balkan II, Yemisen M, Mete B, et al
    Reactivation of Hepatitis B Virus Following Treatment of Hepatitis C Virus Infection in Coinfected Patients.
    Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
    PubMed    


  151. BUTT AA, Yan P, Chew KW, Currier J, et al
    Risk of Acute Myocardial Infarction Among HCV+ and HCV- Men at Various Lipid Levels: Results from ERCHIVES.
    Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
    PubMed     Abstract available


  152. TIEN PC
    HCV-associated Alterations in Lipid and Lipoprotein levels: Helpful or Harmful to the Heart?
    Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
    PubMed    


  153. CANARY L, Hariri S, Campbell C, Young R, et al
    Geographic disparities in access to syringe services programs among young people with hepatitis C virus infection in the U.S.
    Clin Infect Dis. 2017 Apr 11. doi: 10.1093.
    PubMed     Abstract available


  154. MORRIS MD, Shiboski S, Bruneau J, Hahn JA, et al
    Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration.
    Clin Infect Dis. 2017;64:860-869.
    PubMed     Abstract available


  155. NOSKA AJ, Belperio PS, Loomis TP, O'Toole TP, et al
    Prevalence of HIV, HCV and HBV among Homeless and Non-homeless United States Veterans.
    Clin Infect Dis. 2017 Apr 1. doi: 10.1093.
    PubMed     Abstract available


    March 2017
  156. WYLES D, Brau N, Kottilil S, Daar ES, et al
    Sofosbuvir and Velpatasvir for the Treatment of HCV in Patients Coinfected with HIV-1: an Open-Label, Phase 3 Study.
    Clin Infect Dis. 2017 Mar 29. doi: 10.1093.
    PubMed     Abstract available


  157. BUTT AA, Ren Y, Lo Re V 3rd, Taddei T, et al
    Comparing Child-Pugh, MELD and FIB-4 to Predict Clinical Outcomes in HCV-Infected Persons: Results from ERCHIVES.
    Clin Infect Dis. 2017 Mar 22. doi: 10.1093.
    PubMed     Abstract available


  158. CEPEDA JA, Thomas DL, Astemborski J, Sulkowski MS, et al
    Increased mortality among persons with chronic hepatitis C with moderate or severe liver disease: a cohort study.
    Clin Infect Dis. 2017 Mar 10. doi: 10.1093.
    PubMed     Abstract available


  159. HEZODE C, Fourati S, Chevaliez S, Scoazec G, et al
    Sofosbuvir-Daclatasvir-Simeprevir plus Ribavirin in Direct-Acting Antiviral-Experienced Hepatitis C Patients.
    Clin Infect Dis. 2017 Mar 10. doi: 10.1093.
    PubMed     Abstract available


    February 2017
  160. NAGGIE S, Marks KM, Hughes M, Fierer DS, et al
    Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.
    Clin Infect Dis. 2017 Feb 27. doi: 10.1093.
    PubMed     Abstract available


  161. VINIKOOR MJ, Sinkala E, Chilengi R, Mulenga L, et al
    Impact of antiretroviral therapy on liver fibrosis among HIV-infected adults with and without HBV coinfection in Zambia.
    Clin Infect Dis. 2017 Feb 4. doi: 10.1093.
    PubMed    


    August 2016
  162. WITTKOP L
    Endstage liver disease in HIV infection: an avoidable burden?
    Clin Infect Dis. 2016.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: